Schrödinger Raises 2026 ACV Guidance to $222 Million-$232 Million

• Schrödinger raised its 2026 annual contract value guidance to $222 million–$232 million, representing 12%–17% growth.
• Drug discovery revenue is now forecast at $75 million–$85 million, up from $65 million–$75 million.
• Operating expenses are expected to be lower than in 2025.
• Third-quarter 2026 revenue rose 19% to $64.5 million, supporting the improved outlook.
• The company targets positive adjusted EBITDA by the end of 2028, with annual contract value growth of 10%–15% annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.